PD
TRDA icon

Point72 (DIFC)’s Entrada Therapeutics TRDA Stock Holding History

Point72 (DIFC)’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$7.88K Buy
+1,358
New +$7.95K ﹤0.01% 966

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Point72 (DIFC)'s TRDA Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Entrada Therapeutics (TRDA) in Q3 2025: 1,358 shares worth $7.88K. The stake represents ﹤0.01% of the portfolio and ranks #966 among its holdings.

117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • Point72 (DIFC) held 1,358 shares of Entrada Therapeutics worth $7.88K as of Q3 2025.
  • Entrada Therapeutics was a new Point72 (DIFC) position in Q3 2025.
  • Entrada Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #966 holding.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.